VCB Technology platform is broadly applicable across many drug categories; each of our candidates is based on the established chemistry innovation utilizing one of the major n-3 essential fatty acids as one bioactive in the molecular conjugate design and also developing novel molecular conjugation forms of existing medicines to enhance their drug profile and patient compliance. Application of our VCB Technology is an efficient way to overcome the deficits of existing medicines on the market to create new medicines with pharmacokinetic, pharmacodynamic and physicochemical properties that enable new therapeutic indications with long-term, patent-protected commercial viability.
We believe that our VCB technology platform provides significant enhancements over preceding methods to molecular conjugation and has the potential to:
- Improve activity on disease pathways through modulation of multiple biological targets
- Enhance efficacy by matching the pharmacokinetics and tissue distribution of the component active moieties
- Advance safety and tolerability by releasing the component active moieties only within cells
As prodrug (molecular conjugate) / ionic salt forms in the new molecular entities (NMEs), the compounds completely hydrolyze / dissociate into their component entities in gastric fluids, precluding exposure of systemic tissues to the NME. These properties enables VClinBio to reduce the cost, risk and time typically required in order to begin clinical studies. The reason for these efficiencies is that the established safety credentials of the biologically active agents and the NME provide the foundation for regulatory efficiencies in the non-clinical safety package and the development and registration programs.
Our drug product candidates have strong intellectual property protection including composition of matter, treatment, process, formulation and physical combination claims. We have composition of matter protection on VCB 101 and VCB 102 under an issued patent (US 9102649 B1).